The calculated fair value of LifeMD stock varies across institutional research models, depending on projected compound annual growth rates for telehealth adoption, gross margin expansions, and cash flow forecasts. While Wall Street consensus twelve-month price targets average between $7.57 and $8.80—suggesting substantial upside relative to its small-cap trading range—fundamental fair value calculations shift dynamically as the company scales its subscription base and works toward sustained net profitability.